Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma

Thibault Dupont, Shao Ning Yang, Jayeshkumar Patel, Katerina Hatzi, Alka Malik, Wayne Tam, Peter Martin, John Leonard, Ari Melnick, Leandro Cerchietti

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The BCL6 oncogene plays a crucial role in sustaining diffuse large B-cell lymphomas (DLBCL) through transcriptional repression of key checkpoint genes. BCL6-targeted therapy kills lymphoma cells by releasing these checkpoints. However BCL6 also directly represses several DLBCL oncogenes such as BCL2 and BCL-XL that promote lymphoma survival. Herein we show that DLBCL cells that survive BCL6-targeted therapy induce a phenomenon of "oncogene-addiction switching" by reactivating BCL2-family dependent anti-apoptotic pathways. Thus, most DLBCL cells require concomitant inhibition of BCL6 and BCL2-family members for effective lymphoma killing. Moreover, in DLBCL cells initially resistant to BH3 mimetic drugs, BCL6 inhibition induces a newly developed reliance on anti-apoptotic BCL2-family members for survival that translates in acquired susceptibility to BH3 mimetic drugs ABT-737 and obatoclax. In germinal center B cell-like (GCB)-DLBCL cells, the proteasome inhibitor bortezomib and the NEDD inhibitor MLN4924 posttranscriptionally activated the BH3-only sensitizer NOXA thus counteracting the oncogenic switch to BCL2 induced by BCL6-targeting. Hence our study indicates that BCL6 inhibition induces an on-target feedback mechanism based on the activation of anti-apoptotic BH3 members. This oncogene-addition switching mechanism was harnessed to develop rational combinatorial therapies for GCB-DLBCL.

Original languageEnglish (US)
Pages (from-to)3520-3532
Number of pages13
JournalOncotarget
Volume7
Issue number3
DOIs
StatePublished - 2016

Fingerprint

Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
Oncogenes
Lymphoma
Proteasome Inhibitors
Germinal Center
Pharmaceutical Preparations
B-Lymphocytes
Therapeutics
Genes
Inhibition (Psychology)

Keywords

  • BCL2
  • BCL6
  • Lymphoma
  • Resistance
  • Targeting

ASJC Scopus subject areas

  • Oncology

Cite this

Dupont, T., Yang, S. N., Patel, J., Hatzi, K., Malik, A., Tam, W., ... Cerchietti, L. (2016). Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget, 7(3), 3520-3532. https://doi.org/10.18632/oncotarget.6513

Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. / Dupont, Thibault; Yang, Shao Ning; Patel, Jayeshkumar; Hatzi, Katerina; Malik, Alka; Tam, Wayne; Martin, Peter; Leonard, John; Melnick, Ari; Cerchietti, Leandro.

In: Oncotarget, Vol. 7, No. 3, 2016, p. 3520-3532.

Research output: Contribution to journalArticle

Dupont, T, Yang, SN, Patel, J, Hatzi, K, Malik, A, Tam, W, Martin, P, Leonard, J, Melnick, A & Cerchietti, L 2016, 'Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma', Oncotarget, vol. 7, no. 3, pp. 3520-3532. https://doi.org/10.18632/oncotarget.6513
Dupont, Thibault ; Yang, Shao Ning ; Patel, Jayeshkumar ; Hatzi, Katerina ; Malik, Alka ; Tam, Wayne ; Martin, Peter ; Leonard, John ; Melnick, Ari ; Cerchietti, Leandro. / Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. In: Oncotarget. 2016 ; Vol. 7, No. 3. pp. 3520-3532.
@article{627a66fff31a4a86b056820594808824,
title = "Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma",
abstract = "The BCL6 oncogene plays a crucial role in sustaining diffuse large B-cell lymphomas (DLBCL) through transcriptional repression of key checkpoint genes. BCL6-targeted therapy kills lymphoma cells by releasing these checkpoints. However BCL6 also directly represses several DLBCL oncogenes such as BCL2 and BCL-XL that promote lymphoma survival. Herein we show that DLBCL cells that survive BCL6-targeted therapy induce a phenomenon of {"}oncogene-addiction switching{"} by reactivating BCL2-family dependent anti-apoptotic pathways. Thus, most DLBCL cells require concomitant inhibition of BCL6 and BCL2-family members for effective lymphoma killing. Moreover, in DLBCL cells initially resistant to BH3 mimetic drugs, BCL6 inhibition induces a newly developed reliance on anti-apoptotic BCL2-family members for survival that translates in acquired susceptibility to BH3 mimetic drugs ABT-737 and obatoclax. In germinal center B cell-like (GCB)-DLBCL cells, the proteasome inhibitor bortezomib and the NEDD inhibitor MLN4924 posttranscriptionally activated the BH3-only sensitizer NOXA thus counteracting the oncogenic switch to BCL2 induced by BCL6-targeting. Hence our study indicates that BCL6 inhibition induces an on-target feedback mechanism based on the activation of anti-apoptotic BH3 members. This oncogene-addition switching mechanism was harnessed to develop rational combinatorial therapies for GCB-DLBCL.",
keywords = "BCL2, BCL6, Lymphoma, Resistance, Targeting",
author = "Thibault Dupont and Yang, {Shao Ning} and Jayeshkumar Patel and Katerina Hatzi and Alka Malik and Wayne Tam and Peter Martin and John Leonard and Ari Melnick and Leandro Cerchietti",
year = "2016",
doi = "10.18632/oncotarget.6513",
language = "English (US)",
volume = "7",
pages = "3520--3532",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "3",

}

TY - JOUR

T1 - Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma

AU - Dupont, Thibault

AU - Yang, Shao Ning

AU - Patel, Jayeshkumar

AU - Hatzi, Katerina

AU - Malik, Alka

AU - Tam, Wayne

AU - Martin, Peter

AU - Leonard, John

AU - Melnick, Ari

AU - Cerchietti, Leandro

PY - 2016

Y1 - 2016

N2 - The BCL6 oncogene plays a crucial role in sustaining diffuse large B-cell lymphomas (DLBCL) through transcriptional repression of key checkpoint genes. BCL6-targeted therapy kills lymphoma cells by releasing these checkpoints. However BCL6 also directly represses several DLBCL oncogenes such as BCL2 and BCL-XL that promote lymphoma survival. Herein we show that DLBCL cells that survive BCL6-targeted therapy induce a phenomenon of "oncogene-addiction switching" by reactivating BCL2-family dependent anti-apoptotic pathways. Thus, most DLBCL cells require concomitant inhibition of BCL6 and BCL2-family members for effective lymphoma killing. Moreover, in DLBCL cells initially resistant to BH3 mimetic drugs, BCL6 inhibition induces a newly developed reliance on anti-apoptotic BCL2-family members for survival that translates in acquired susceptibility to BH3 mimetic drugs ABT-737 and obatoclax. In germinal center B cell-like (GCB)-DLBCL cells, the proteasome inhibitor bortezomib and the NEDD inhibitor MLN4924 posttranscriptionally activated the BH3-only sensitizer NOXA thus counteracting the oncogenic switch to BCL2 induced by BCL6-targeting. Hence our study indicates that BCL6 inhibition induces an on-target feedback mechanism based on the activation of anti-apoptotic BH3 members. This oncogene-addition switching mechanism was harnessed to develop rational combinatorial therapies for GCB-DLBCL.

AB - The BCL6 oncogene plays a crucial role in sustaining diffuse large B-cell lymphomas (DLBCL) through transcriptional repression of key checkpoint genes. BCL6-targeted therapy kills lymphoma cells by releasing these checkpoints. However BCL6 also directly represses several DLBCL oncogenes such as BCL2 and BCL-XL that promote lymphoma survival. Herein we show that DLBCL cells that survive BCL6-targeted therapy induce a phenomenon of "oncogene-addiction switching" by reactivating BCL2-family dependent anti-apoptotic pathways. Thus, most DLBCL cells require concomitant inhibition of BCL6 and BCL2-family members for effective lymphoma killing. Moreover, in DLBCL cells initially resistant to BH3 mimetic drugs, BCL6 inhibition induces a newly developed reliance on anti-apoptotic BCL2-family members for survival that translates in acquired susceptibility to BH3 mimetic drugs ABT-737 and obatoclax. In germinal center B cell-like (GCB)-DLBCL cells, the proteasome inhibitor bortezomib and the NEDD inhibitor MLN4924 posttranscriptionally activated the BH3-only sensitizer NOXA thus counteracting the oncogenic switch to BCL2 induced by BCL6-targeting. Hence our study indicates that BCL6 inhibition induces an on-target feedback mechanism based on the activation of anti-apoptotic BH3 members. This oncogene-addition switching mechanism was harnessed to develop rational combinatorial therapies for GCB-DLBCL.

KW - BCL2

KW - BCL6

KW - Lymphoma

KW - Resistance

KW - Targeting

UR - http://www.scopus.com/inward/record.url?scp=84962263699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962263699&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.6513

DO - 10.18632/oncotarget.6513

M3 - Article

C2 - 26657288

AN - SCOPUS:84962263699

VL - 7

SP - 3520

EP - 3532

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 3

ER -